# US 10,117,856 B2 · Methods of treatment for cholestatic and fibrotic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,856 B2
- Document ID: US10117856B2
- Status: Granted
- Kind: B2
- Application number: 15/841,981
- Filed: 2017-12-14
- Published: 2018-04-05
- Granted: 2018-11-06
- Earliest claimed: 2016-04-11
- Assignees: Genfit
- Applicants: Genfit
- Inventors: Raphael Darteil; Robert Walczak; Carole Belanger; Emilie Negro; Pierre Daubersies; Philippe Delataille
- Web page: https://patentgrep.com/patent/US10117856B2

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.

## Claims

### Claim 1

A method for treating intestinal fibrosis comprising administering to a subject in need thereof a therapeutic effective amount of a compound selected in the group consisting of Nitazoxanide (NTZ), Tizoxanide (TZ), and a pharmaceutically acceptable salt of NTZ or TZ.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is administered orally.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound is administered in an amount comprised between 100 mg/day and 2000 mg/day.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound is administered in the form of a pharmaceutical composition providing prolonged or slow release of the compound.

### Claim 5 (depends on 1)

The method according to claim 1, wherein intestinal fibrosis is small intestine fibrosis.

### Claim 6

A method for treating intestinal fibrosis comprising administering to a subject in need thereof a therapeutic effective amount of nitazoxanide.

### Claim 7 (depends on 6)

The method according to claim 6, wherein nitazoxanide is administered orally.

### Claim 8 (depends on 6)

The method according to claim 6, wherein nitazoxanide is administered in an amount comprised 100 mg/day and 2000 mg/day.

### Claim 9 (depends on 6)

The method according to claim 6, wherein nitazoxanide is administered in the form of a pharmaceutical composition providing prolonged or slow release of nitazoxanide.

### Claim 10 (depends on 6)

The method according to claim 6, wherein intestinal fibrosis is small intestine fibrosis.